期刊文献+

2型糖尿病患者发生血管并发症的危险因素分析 被引量:18

Risk factors for vascular complications in patients with type 2 diabetes mellitus
下载PDF
导出
摘要 目的分析2型糖尿病患者血管并发症的相关因素。方法选取2016年5月至2017年5月间武警广西总队医院内分泌科诊治的100例2型糖尿病患者为研究对象,根据尿酸水平是否升高分为观察组和对照组,每组50例,收集和分析两组患者的临床资料,比较两组患者血管并发症发生情况,并采用Logistics多因素回归分析法对2型糖尿病患者发生血管并发症危险因素进行分析。结果观察组患者的体质指数(BMI)、糖化血糖蛋白(Hb A1c)、甘油三酯(TG)、胆固醇(TC)、C反应蛋白(CRP)、白介素-6(IL-6)、肿瘤坏死因子(TNF)尿素氮(BUN)、肌酐(Cr)、收缩压(SBP)均明显高于对照组,肾小球滤过率(e-GFR)明显低于对照组,差异均有统计学意义(P<0.05);观察组患者的高血压、冠心病、脑卒中、糖尿病视网膜病变/糖尿病肾病及下肢动脉病变发生率均明显高于对照组,差异均有统计学意义(P<0.05);Logistics多因素回归分析结果显示,尿酸、病程、Hb A1c、SBP为2型糖尿病患者血管并发症独立危险因素(P<0.05)。结论高尿酸血症、病程、Hb A1c、SBP是2型糖尿病患者血管并发症的独立危险因素。 Objective To analyze the risk factors for vascular complications in patients with type 2 diabetes mellitus Methods A total of 100 patients with type 2 diabetes from May 2016 to May 2017 in Department of Endocrinology, Guangxi General Team Hospital of Armed Police Corps were selected and divided into observation group and control group according to whether the uric acid level was elevated or not, with 50 cases in each group. The clinical data were collected and analyzed, and the incidences of vascular complications were compared between the two groups. Logistic regression analysis was used to analyze the risk factors of vascular complication in patients with type 2 diabetes.Results Body mass index(BMI), glycosylated glucose protein(Hb A1 c), triglyceride(TG), cholesterol(TC), C reactive protein(CRP), interleukin-6(IL-6), tumor necrosis factor(TNF), blood urea nitrogen(BUN), creatinine(Cr), systolic pressure(SBP) in the observation group were higher than those in the control group, and the glomerular filtration rate(e-GFR) was significantly lower than that in the control group(P〈0.05). The incidence of hypertension, coronary heart disease, stroke, diabetic retinopathy, diabetic nephropathy and lower extremity arterial disease in the observation group were significantly higher than those in control group(P〈0.05). Logistic regression analysis showed that uric acid, duration of disease, Hb A1 c and SBP were independent risk factors of vascular complications in type 2 diabetes mellitus(P〈0.05). Conclusion Uric acid, duration of disease, Hb A1 c and SBP are the independent risk factors of vascular complications in patients with type 2 diabetes mellitus.
作者 白慧华 周铸 邓楠 BAI Hui-hua;ZHOU Zhu;DENG Nan(Department of Endocrinolog;Department of General Surgery Outpatient and Emergenc;Department Guangxi General Team Hospital of Armed Police Corps, Nanning 530012, Guangxi, CHINA)
出处 《海南医学》 CAS 2018年第13期1802-1804,共3页 Hainan Medical Journal
关键词 尿酸 2型糖尿病 血管 并发症 Uric acid Type 2 diabetes mellitus Blood vessel Complication
  • 相关文献

参考文献9

二级参考文献82

  • 1Heart Protection Study Collaborative Group, Jonathan Emberson, Derrick Bennett,et al. C -reactive protein concentration and the vascular benefits of statin therapy:an analysis of 20,536 patients in the Heart Protection Study [ J ]. Lancet ,2011,377 (9764) :469 - 476.
  • 2Goto Y,Hotta N? Shigeta Y, et al. Effects of an aldose reduc-tase inhibitor, epalrestat, on diabetic neuropathy. Clinical ben-efit and indication for the drug assessed from the results of aplacebo-controlled double-blind study. Biomed Pharmacother,1995, 49 r 269-277.
  • 3Hotta N,Akanuma Y,Kawamori R, et al. Long-term clinicaleffects of epalrestat, an aldose reductase inhibitor, on diabeticperipheral neuropathy: the 3-year, multicenter, comparativeAldose Reductase Inhibitor^Diabetes Complications Trial. Dia-betes Care, 2006, 29:1538-1544.
  • 4Ikeda T, Iwata K,Tanaka Y. Long-term effect of epalrestaton cardiac autonomic neuropathy in subjects with non-insulindependent diabetes mellitus. Diabetes Res Clin Pract, 1999,43:193-198.
  • 5Nakayama M, Nakamura J, Hamada Y, et al. Aldose reduc-tase inhibition ameliorates pupillary light reflex and F-wave la-tency in patients with mild diabetic neuropathy. Diabetes Care,2001, 24:1093-1098.
  • 6Ziegler D, Mayer P, Rathmann W, et al. One-year treatmentwith the aldose reductase inhibitor, ponalrestat, in diabeticneuropathy. Diabetes Res Clin Pract, 1991,14:63-73.
  • 7Gingliano D, Marfella R,Quatraro A, et al. Tolrestat for milddiabetic neuropathy. A 52-week, randomized> placebo-con-trolled trial. Ann Intern Med, 1993,118:7-11.
  • 8Giugliano D, Acampora R, Marfella R, et al. Tolrestat in theprimary prevention of diabetic neuropathy. EHabetes Care,1995,18-536-541.
  • 9Faes TJ, Yff GA, DeWeerdt 0,et al. Treatment of diabeticautonomic neuropathy with an aldose reductase inhibitor. JNeurol, 1993, 240: 156-160.
  • 10Sundkvist G, Armstrong FM, Bradbury JE, et al. Peripheraland autonomic nerve function in 259 diabetic patients with pe-ripheral neuropathy treated with ponalrestat (an aldose reduc-tase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial. J Diabetes Complications,1992, 6:123-130.

共引文献68

同被引文献156

引证文献18

二级引证文献99

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部